ArticleCancer2025
Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThis study assesses the incidence and timing of undetectable prostate-specific antigen (PSA) after radiotherapy (RT) ± androgen deprivation therapy (ADT) and its association with prostate cancer mortality.
methodsThis is a population-based study including 5299 men undergoing RT (2006-2020) in the Stockholm County, Sweden with all their PSA tests until death or emigration. The authors calculated incidence and timing of undetectable PSA (PSA ≤0.1 ng/mL) and used competing risk regression to evaluate the association of detectable PSA at 6 and 12 months with prostate cancer mortality (PCSM).
resultsMedian follow-up for survivors was 81 (32, 130) months. PSA nadir values were reached before 6 and 12 months in 233 (23%) and 470 (36%) patients undergoing RT and 2871 (85%) and 3612 (90%) patients undergoing RT+ADT. No significant association was found between PSA at nadir, 6 and 12 months and PCSM in the radiotherapy group and evidence of association with higher PCSM in RT+ADT group (PSA at nadir: subdistribution hazard ratio [sHR], 2.23 [2.01-2.49]; PSA at 6 months: sHR, 6.91 [5.17-9.23]; and PSA at 12 months: sHR, 37.9 [23.0-62.5]). At 12 years after RT + ADT, PCSM rates were 27%, 15%, 13%, and 5% for patients with PSA at 6 months of ≥0.5, 0.2-0.5, 0.1-0.2, and ≤0.1 ng/mL, respectively; corresponding rates by PSA at 12 months were 34%, 18%, 12%, and 5%.
conclusionsMost patients undergoing RT+ADT reached a PSA ≤0.1 ng/mL within 6 and 12 months. PSA>0.1 ng/mL at these time points indicated a higher risk of PCSM, emphasizing the need for timely restaging and intensified salvage treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.